You are here: Industry Insights > Pfizer

News List

Pfizer's Inlyta fails to prolong disease-free survival in Phase III study of patients at risk of recurrent kidney cancer firstwordpharma
April 11, 2018
Pfizer on Tuesday announced that it will halt a late-stage study evaluating Inlyta (axitinib) as adjuvant therapy for patients at high risk of recurrent renal cell carcinoma (RCC) after nephrectomy
Pfizer and Allogene Therapeutics enter into asset contribution agreement for Pfizer's allogeneic CAR T immuno-oncology portfolio worldpharmanews
April 09, 2018
Pfizer Inc today announced that the two companies have entered into an asset contribution agreement for Pfizer's portfolio of assets related to allogeneic chimeric antigen receptor T cell (CAR T) therapy
Pfizer announces trial success for rare cardiac disease drug pharmaceutical-technology
April 09, 2018
Pfizer has announced positive results from its Phase III study of experimental drug tafamidis in patients with transthyretin cardiomyopathy.
Pfizer, Allogene Therapeutics Enter into Asset Contribution Agreement americanpharmaceuticalreview
April 09, 2018
Pfizer and Heterologous Therapeutics Announce the Agreement between Pfizer and Allo-Chimeric Antigen Receptor T Cell (CAR T) Treatment Related Assets
Pfizer Announces Positive Topline Results From Phase 3 ATTR-ACT Study Of Tafamidis In Patients With Transthyretin Cardiomyopathy biospace
March 30, 2018
Pfizer Inc. announced today that the Phase 3 transthyretinopathy cardiomyopathy (ATTR-ACT) study in Tafamidis evaluates tafamyline treatment for transthyretin-induced cardiomyopathy in accordance with its primary endpoint
GSK passes up Pfizer consumer buy, shares rise pharmaphorum
March 27, 2018
GlaxoSmithKline’s chief executive Emma Walmsley has just taken one of her most challenging decisions to date– and it look like investors are backing her.
Pfizer Reports Top-Line Results from a Study of CHANTIX®/CHAMPIX® (varenicline) in Adolescent Smokers biospace
March 26, 2018
Pfizer Inc. announced today results from a Phase 4 study evaluating the efficacy and safety of CHANTIX®/CHAMPIX®(varenicline) for smoking cessation in nicotine dependent adolescents 12-19 years of age.
GSK Walks Away From Acquiring Pfizer Consumer Goods Unit biospace
March 26, 2018
GlaxoSmithKline will not make a play for Pfizer’s consumer health business.
GSK Is Now Favorite to Acquire Pfizer's Consumer Health Business biospace
March 23, 2018
GlaxoSmithKline may have an easier path to acquiring Pfizer Inc.’s consumer health business after a rival suitor walked away from making a deal with the pharma giant.
USFDA grants priority to XTANDI's sNDA biospectrumasia
March 21, 2018
When approved, the sNDA would expand the indication of XTANDI to include men with non-metastatic Castration-Resistant Prostate Cancer

Previous page 1 2 3 4 5 6 7 8 9 10 ... 83 84 Next page